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The prevalence of cardiometabolic diseases (CMD) such as atherosclerotic cardiovascular 
diseases, type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD), has grown 
dramatically during the last decades. Hence, massive research efforts are allocated to identify 
the pathophysiological mechanisms and new therapeutic targets for these morbidities. 
However, the data gained from preclinical studies using in vitro cellular or in vivo animal 
models are not always clinically translatable. The overall aim of this thesis was to develop 
and characterize new experimental models relevant to the human condition with respect to 
liver and lipoprotein metabolism, and to use these models to validate new therapeutic targets 
to treat CMD. 
Various strains of mice, genetically altered or unaltered, are extensively used to study human 
CMD. However, major species differences limit the human translatability of animal models. 
In Papers I and II we thoroughly characterized the lipoprotein and liver metabolism of liver-
humanized mice (LHM), a promising preclinical model to study human hepatic metabolism. 
To generate LHM, immunocompromised Fah/Rag2/Il2rg-triple knockout mice on the 
nonobese diabetic background are repopulated with human hepatocytes. Cholesterol 
lipoprotein profiles of LHM showed a human-like pattern, shifting the cholesterol transport 
into low-density lipoprotein (LDL) rather than in high-density lipoprotein particles. The 
humanization of lipoprotein profiles does not require cholesteryl ester transfer protein, and 
was instead determined by higher levels of apolipoprotein B100 in the circulation, as a result 
of lower hepatic mRNA editing and LDL receptor expression, and higher levels of circulating 
proprotein convertase subtilisin/kexin type 9. As a consequence, LHM lipoproteins bind to 
human aortic proteoglycans in a pattern similar to human lipoproteins, which entails the 
potential use of LHM as a model for studies of atherosclerosis. A human-like bile acid 
metabolism was also observed in LHM, with higher levels of glycine-conjugated bile acids 
and taurodeoxycholic acid, and lower levels of mouse-specific tauromuricholic acids. 
However, an altered enterohepatic signaling in LHM results in abnormal bile acid synthesis. 
We also investigated the response to pharmacological and dietary stimuli in LHM. When 
treated with the liver X receptor (LXR) agonist GW3965, LHM mimicked the negative lipid 
outcomes seen in the first human trial of LXR stimulation, and thus allowed the 
characterization of the hepatic effects at a molecular level. To induce CMD in mouse models, 
challenge with high-fat/high-sucrose diet (HFHSD) is often used. However, LHM appeared 
to be resistant to HFHSD. We also present the preliminary results on the development of 
sever hepatic steatosis and atherosclerosis after feeding LHM with a high-fat/high-
fructose/high-cholesterol diet. Taken together, these results indicate LHM as an interesting 
translatable model of human hepatic and lipoprotein metabolism. Because several metabolic 
parameters displayed donor dependency, LHM may also be used for studies of personalized 
medicine. 
Human hepatocyte-like cell lines (such as HepG2, Huh7 and Huh7.5 cells) are also widely 
used in preclinical research to study CMD. However, these cell lines exhibit major 
differences compared with human hepatocytes in vivo. For instance, hepatocytes in vivo only 
express sterol-O acyltransferase (SOAT) 2, whereas both SOAT1 and SOAT2 are found in 
HepG2, Huh7 and Huh7.5 cells. SOAT1 and SOAT2 catalyze the formation of cholesteryl 
esters, but only SOAT2 determines the amount of CE secreted in apolipoprotein B-containing 
lipoproteins. Therefore, in Paper III we used the clustered regularly interspaced short 
palindromic repeats (CRISPR) technology to knock out SOAT1 in HepG2 and Huh7.5 cells. 
Moreover, culturing HepG2 cells with medium supplemented with human instead of fetal 
bovine serum dramatically improves the lipid and lipoprotein metabolism. Hence, unedited 
and SOAT2-only cells were cultured with either fetal bovine or human serum to assess 
whether the combination of SOAT1-KO with culturing with human serum could additionally 
improve the phenotype of HepG2 and Huh7.5 cells. SOAT2-only-HepG2 cells exhibited 
higher levels of cholesterol, triglycerides and apolipoprotein B in the medium compared with 
unedited HepG2 cells. Further increase was seen when culturing SOAT2-only-HepG2 cells 
with human serum. Opposite effects were instead found in SOAT2-only-Huh7.5 cells. This 
study shows that SOAT1 expression in hepatocyte-like cells contributes to the distorted 
phenotype observed in HepG2 and Huh7.5 cells. SOAT2-only-HepG2 cells cultured with 
human serum represent an improved model for studies of human hepatic lipid metabolism. 
Inhibition of the lipid droplet-associated gene cell death-inducing DFFA-like effector c 
(CIDEC) has been proposed as a therapeutic strategy for hepatic steatosis and NAFLD. 
Hence, in Paper IV we knocked out CIDEC in HepG2 cells using the CRISPR technology in 
order to study its potential role as therapeutic target for hepatic steatosis/NAFLD. Knockout 
of CIDEC in HepG2 cells was accompanied by changes in the expression of several 
mediators of lipid metabolism. Nonetheless, the intracellular levels of cholesterol and 
triglycerides were not affected. Future studies will elucidate the role of CIDEC in hepatic 
lipid and carbohydrate metabolism and its potential as a therapeutic target for hepatic 
steatosis. 
Collectively, these results highlight LHM and SOAT2-only-HepG2 cells cultured with human 
serum as new preclinical models that greatly improve the translatability into humans 
compared with the commonly used in vivo and in vitro models.  
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1.1 CARDIOMETABOLIC DISEASES 
Cardiometabolic diseases (CMD) are defined as a cluster of metabolic disorders leading to 
atherosclerotic cardiovascular diseases (ASCVD) and type 2 diabetes mellitus (T2D).1 
Several metabolic diseases are strongly associated with atherosclerosis and cardiovascular 
risk, including visceral obesity, hypertension, dyslipidemia, insulin resistance and 
nonalcoholic fatty liver disease (NAFLD).2-4 Moreover, progression of atherosclerosis leads 
to the most common form of ASCVD, and is promoted by an impaired lipid metabolism.2, 4, 5 
Over the last fifty years, the prevalence of CMD has grown dramatically due to the increase 
of life expectancy and cultural transitions in lifestyle and nutrition – also in low- and middle-
income countries – causing a massive economic burden for the healthcare systems 
worldwide.3, 4, 6 According to the mortality estimates from World Health Organization 
(WHO) outlined in Figure 1.1, in 2000 around 14 million deaths worldwide were caused by 
CMD (i.e., ischemic heart disease, stroke, T2D and hypertensive heart disease), 
corresponding to 26% of total deaths.7 By the year 2016, deaths caused by CMD increased to 
around 18 million (31% of total deaths) (Figure 1.1).7 As a confirmation of this 
interrelationship, CMD and ASCVD share similar risk factors, classified in (a) behavioral 
(smoking, physical inactivity, unbalanced diet, and excess of alcohol), (b) metabolic 
(dyslipidemia, hypertension, insulin resistance, and obesity), and (c) others (age, sex, genetic 
disposition, stress, poverty, and low education).2 
According to WHO, there is strong evidence that behavioral and metabolic risk factors play a 
key role in the etiology of ASCVD (and thus CMD).2, 4 Therefore, the first-line intervention 
to prevent ASCVD and mitigate the cardiometabolic risk consists of a healthy lifestyle that 
includes a low-fat diet and regular physical activity.2, 4 
 
  
Figure 1.1 Estimates of worldwide deaths by CMD in 2000-2016. Data from Global Health Estimates 2016 
from the WHO.7 CMD (in red) represents the sum of the total death estimates from ischemic heart disease, 
stroke, T2D and hypertensive heart disease. 
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1.1.1 Lipoproteins and atherosclerotic cardiovascular diseases 
Lipids, such as triglycerides (TGs) and cholesterol, are fundamental biological molecules. 
However, impaired lipid homeostasis in the organism represents a critical risk factor for 
CMD.2, 4 Because lipids are insoluble in water, they are packaged with protein components 
named apolipoproteins (APOs) in lipoprotein complexes for transportation in the 
bloodstream. There are multiple classes of APOs, which determine the structural and 
functional properties of the particles, affect plasma uptake and clearance, and serve as 
enzyme activators or inhibitors.4 Lipoproteins are commonly classified by their density, and 
can further be divided in two main groups containing either APOB or APOA1. APOB is 
present in all atherogenic particles, i.e., chylomicrons, chylomicron remnants, very low-
density lipoproteins (VLDLs), intermediate-density lipoproteins (IDLs), low-density 
lipoproteins (LDLs), and lipoprotein(a) (Lp(a)).4 APOA1-containing particles include high-
density lipoproteins (HDLs), which are considered atheroprotective due to their 
functionalities (e.g., anti-inflammatory and antioxidant activity and cholesterol efflux 
capacity (CEC)).4, 8 
The atherogenicity of APOB-containing lipoproteins is explained by the interaction of APOB 
with sub-endothelial (or intima) proteoglycans (PG).5 APOB binding retains the lipoprotein 
particle in the arterial wall,5 triggering the first step in early atherogenesis according to the 
“response-to-retention” hypothesis.9, 10 Because large chylomicron and VLDL particles 
cannot penetrate the endothelium – in contrast to their remnants and LDLs – the size of the 
particle is determining its retention within the intima.4 Therefore, the main traditional risk 
factor for ASCVD in the general population is represented by high plasma levels of LDL-
cholesterol.4 In 2017, the overall evidence from genetic, epidemiological, Mendelian 
randomization, and randomized trials of LDL-cholesterol-lowering therapies, led a consensus 
panel from the European Atherosclerosis Society to state that LDL-cholesterol is causative of 
ASCVD.4, 11, 12 
Nonetheless, in individuals with metabolic disorders such as T2D, high plasma levels of TGs 
(or TG-rich lipoprotein remnants) and low HDL-cholesterol also increase the cardiometabolic 
risk.4 These two features are often associated with one another, and low HDL-cholesterol 
levels have been shown to be a strong risk factor for ASCVD.4 However, genetic studies 
suggest that HDL-cholesterol has no role for ASCVD, whereas elevated remnant cholesterol 
(i.e., the cholesterol contained in TG-rich lipoproteins) is a causal risk factor for ASCVD.4, 13 
Furthermore, both LDL-cholesterol and remnant cholesterol are causally associated with 
ASCVD, but only remnant cholesterol is also causally associated with low-grade 
inflammation.13 This suggests TGs to prompt the inflammatory component in the 
atherosclerosis process. 
1.1.2 Liver and cardiometabolic diseases 
The liver has a key role in the regulation of cholesterol and lipoprotein homeostasis. 
Cholesterol is a fundamental biological molecule, being a crucial constituent of biological 
membranes where it promotes proper membrane fluidity and permeability, and it produces 
“rafts” involved in endocytosis and cell signaling.14 Moreover, cholesterol is precursor of bile 
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acids (BAs), oxysterols (i.e., oxygenated derivatives of cholesterol), steroid hormones and 
vitamin D, which can act as regulators of the transcriptional response and affect several vital 
functions. Cholesterol has also a role during the embryonic development, as is used as a 
substrate to modify covalently several signaling mediators (e.g., hedgehog proteins). 
Alterations of the cholesterol biosynthesis, both during the development and in the adult state, 
may lead to severe malformations and diseases.15 
As comprehensively outlined,16 cholesterol (as many lipids) can be both produced de novo 
(endogenous pathway) or absorbed in the intestine, the latter coming from the diet or the 
enterohepatic circulation (exogenous pathway). Excretion pathways maintain the balance 
between the synthesis and the absorption of cholesterol.  
1.1.2.1 Endogenous pathway 
The biochemical pathway for the synthesis of cholesterol was elucidated by Bloch in the 
1960s.17 Cholesterol biosynthesis begins with the condensation of one molecule of acetyl-
coenzyme A and one molecule of acetoacetyl-coenzyme A to produce 3-hydroxy-3-
methylglutaryl-coenzyme A (HMGC) by HMGC synthase. HMGC is reduced to mevalonate 
by the rate-limiting enzyme HMGC reductase (HMGCR), anchored to endoplasmic reticulum 
membrane.18 Mevalonate is then transformed into isopentenyl pyrophosphate, which is the 
substrate for subsequent polymerizations and modifications leading to the synthesis of 
cholesterol. 
In human hepatocytes, free (or unesterified) cholesterol (FC) is transported to the 
endoplasmic reticulum, and is esterified with fatty acyl-coenzyme A by sterol O-
acyltransferase (SOAT) 2. Cholesteryl esters (CEs) can then be stored in lipid droplets inside 
the cell or packed together with TGs, phospholipids (PL), FC, and APOB100 and secreted in 
the bloodstream as nascent VLDLs. In the circulation, VLDL particles mature by acquiring 
other APOs such as APOE and APOCs: APOE serves as ligand mainly for the LDL receptor 
(LDLR)-related protein 1 (LRP1), allowing the uptake of large and buoyant particles from the 
bloodstream, whereas APOCs affect the lipolysis of the TGs contained in the particle.19 
VLDLs are rapidly taken up via the VLDL receptor (VLDLR), which is widely expressed in 
adipose tissues, heart, muscle, and endothelial cells (but with very low expression in liver).20 
In these tissues, the VLDL uptake leads to the upregulation of lipoprotein lipase (LPL), 
which hydrolyzes VLDL TGs into glycerol and non-esterified fatty acids (NEFA). LPL is 
mainly produced by the adipose, heart and muscle tissue, and it is active at the luminal 
surface of the capillary endothelium of the tissue of origin.21 NEFA enter the tissues to be 
used for energy (muscle) or storage (adipose), or bind to serum albumin to be carried 
throughout the systemic circulation. The decrease in TG content modifies the size and the 
density of VLDLs, which turn into IDLs. The TGs contained in IDLs are mostly hydrolyzed 
by lipase C, hepatic type (LIPC, also known as hepatic lipase, HL), which is produced by the 
liver and it is active in the hepatic endothelia.22 LIPC/HL transforms IDLs in TG-poor and 
cholesterol-rich LDLs, responsible for the movement of cholesterol mainly to peripheral 
tissues. Also, plasma lipid transfer proteins, which include the cholesteryl ester transfer 
protein (CETP) and the phospholipid transfer protein (PLTP), affect lipoprotein concentration 
 
4 
and composition by mediating the transfer of lipids between the different lipoprotein 
particles. CETP exchanges CEs in HDLs for TGs contained in VLDLs or LDLs, whereas 
PLTP transfers surface PL from TG-rich particles to HDLs.23 The liver can take up IDLs and 
LDLs mainly via the LDLR. 
FC and PL can also be secreted to APOA1 by the transporter adenosine triphosphate (ATP)-
binding cassette (ABC) A1, which is expressed on the basolateral membrane of hepatocytes 
and enterocytes, as well as in other tissues. This step is fundamental for the formation of 
HDLs,24 responsible for moving cholesterol from the periphery back to the liver via the 
reverse cholesterol transport (RCT) pathway. In the bloodstream, the lecithin-cholesterol 
acyltransferase (LCAT) esterifies the FC in nascent pre-beta HDLs, contributing to the 
maturation of HDL particles.25 PLTP, CETP and LIPC/HL take also part to HDL 
remodeling.22, 23, 26 Furthermore, HDL particles can exchange APOs and incorporate other 
lipids, thus increasing in size. The hepatocyte takes up the cholesterol in mature HDLs 
mainly via the bidirectional transporter scavenger receptor class B member 1 (SRB1).26 
1.1.2.2 Exogenous pathway 
Cholesterol absorbed in the intestine derives from several sources, including diet, bile, 
intestinal secretion and epithelial cell sheading. Absorption of dietary CEs requires hydrolysis 
and emulsification with BAs to form micelles that are taken up by the enterocytes. 
Cholesterol uptake is facilitated by Niemann-Pick C1-like intracellular cholesterol transporter 
1 (NPC1L1), a transporter located on the apical brush border membrane of enterocytes in the 
proximal small intestine.27 Intestinal cholesterol uptake is antagonized by the obligated 
heterodimer of ABCG5:ABCG8, expressed on the apical membrane of enterocytes where it 
facilitates the efflux of FC back to the intestinal lumen.28 
Similarly to hepatocytes, enterocytes can synthesize cholesterol via HMGCR. Moreover, both 
endogenous and exogenous FC is esterified by SOAT2. FC and CEs are incorporated 
together with TGs, PL and APOB48 into chylomicrons. These lipoproteins are secreted into 
the lymphatic circulation to reach the bloodstream, and transport the dietary lipids to 
peripheral tissues. Here, chylomicrons follow the same fate as VLDLs: they maturate and 
exchange lipids and APOs with other lipoproteins, bind to VLDLR and their TG content is 
hydrolyzed by LPL.29 These modifications lead to the formation of chylomicron remnants, 
particles rich in cholesterol and APOE, that can be taken up by the liver via LDLR or LRP1. 
1.1.2.3 Cholesterol excretion 
In humans, cholesterol cannot be catabolized to produce energy. Therefore, fecal excretion is 
the predominant way for its disposal. The liver excretes the excess of FC into the bile as such 
via ABCG5:ABCG8, which is expressed on the hepatocyte canalicular membrane,30 or after 
its conversion into more soluble BAs. Cytochrome P450 (CYP) 7A1 and CYP27A1 are the 
main rate-limiting enzymes that convert FC to BAs.31 As previously reviewed,32, 33 CYP7A1 
and CYP8B1 are involved in the classical or neutral pathway, which is quantitatively more 
important and favors the synthesis of cholic acid (CA). CYP27A1 and CYP7B1 mediate the 
alternative or acidic pathway, which favors the synthesis of chenodeoxycholic acid in 
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humans, and is present also in extra-hepatic tissues, such as macrophages. In addition, the 
classical and alternative pathways can converge in certain reactions. The BAs synthesized in 
the liver (primary BAs) are conjugated with either glycine or taurine before secretion into the 
gallbladder bile via ABCB11. Humans express NPC1L1 in the bile canaliculi, where it seems 
to mediate the reuptake of biliary FC.34, 35 Primary BAs are partly dehydroxylated into 
secondary BAs by the action of the gut microbiota. Through enterohepatic circulation, BAs 
are resorbed and recycled in the liver. High levels of BAs in the intestine can activate 
farnesoid X receptor (FXR), which leads to secretion of fibroblast growth factor (FGF) 19 (in 
humans, FGF15 in mice). In hepatocytes, both FXR activation and FGF19 binding inhibit the 
BA synthesis. BA homeostasis is therefore maintained by enterohepatic circulation. 
Cholesterol can also be excreted into the feces by a non-biliary pathway known as trans-
intestinal cholesterol excretion (TICE). However, substantial cholesterol secretion from the 
small intestine has been observed only in non-primate animal models. The presence and the 
extent of TICE in humans still require further investigations.36 
1.1.2.4 Regulation of cholesterol homeostasis 
HMGCR is a key enzyme in the regulation of cholesterol homeostasis. It is highly regulated 
through several mechanisms both at transcriptional and post-transcriptional levels.37-40 The 
intracellular amount of FC and oxysterols regulate the HMGCR turnover via the sterol 
regulatory element-binding protein (SREBP) 2, a transcription factor that affects the 
expression of many genes involved in lipid metabolism. The role of SREBP2 was established 
by Goldstein and Brown in the 1990s.41 After its synthesis, SREBP2 binds to SREBP 
cleavage-activating protein (SCAP) in the endoplasmic reticulum. Decrease in the sterol 
levels results in the transport of SCAP-SREBP2 complex to the Golgi, where SREBP2 is 
processed by two serine proteases to release a transcriptionally active N-terminal fragment. 
This fragment migrates to the nucleus, where it binds the sterol regulatory element upstream 
of target genes (e.g., HMGCR, LDLR) and activates the transcription. The opposite, increase 
in the sterol levels leads to the retention of the SCAP-SREBP2 complex. 
Oxysterols seem also to directly regulate cholesterol homeostasis. Although they are present 
at very low physiological levels compared with cholesterol, in biological systems where the 
ratio of the oxysterols to cholesterol is higher than 1:1000 (e.g., brain and cholesterol-loaded 
macrophages) they may activate liver X receptors (LXRs).42 LXR alpha and beta differ for 
the tissue expression patterns, and are able to induce the elimination of cholesterol by 
increasing the expression of target genes involved in cholesterol efflux (e.g., ABCA1, 
ABCG1).43 In addition, LXR activation in mouse liver (but not in humans) increases BA 
synthesis via Cyp7a1.44 
 
Under physiological conditions, cholesterol represents the largest quota of lipids being 
endogenously synthesized.45 Although cholesterol can be synthesized by most cells in the 
body, the liver (and intestine, but to a lesser extent) produces most of the cholesterol. 
Furthermore, only the liver and intestine secrete APOB-containing lipoproteins, thus 
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distributing TGs and cholesterol to the peripheral tissues. For these reasons, the liver and 
intestine are the main targets of dyslipidemia pharmacotherapy.4, 46 When lifestyle 
intervention is not sufficient to reduce ASCVD/CMD risk, the first-choice treatment is the 
use of HMGCR inhibitors – commonly known as statins – which block the rate-limiting step 
in cholesterol biosynthesis.4, 17 Low intracellular levels of FC activate the SREBP2 pathway, 
which in turn induces the expression of LDLR and the uptake of LDLs from plasma.4, 41 
Nonetheless, lifestyle and statin intervention, separately or combined, are not always able to 
completely eliminate the cardiometabolic risk.4, 47 
Perturbations of lipid metabolism can also induce abnormal lipid accumulation (or steatosis) 
in the liver. Hepatic steatosis is indicated as the initial stage of NAFLD when occurring 
without secondary causes such as excessive alcohol consumption, medications, or genetic and 
viral diseases.48, 49 NAFLD is the most common form of chronic liver disease and is 
associated with metabolic comorbidities such as obesity, T2D and dyslipidemias.48, 49 
Moreover, it worsens glycemic control in subjects with T2D, contributes to the development 
and progression of T2D itself and of the most important complications, including ASCVD 
and chronic kidney disease.48, 49 Therefore, NAFLD has been widely accepted as the hepatic 
manifestation of CMD.48, 49 During hepatic steatosis, significant accumulation of lipids 
principally as TGs and CEs within cytoplasmic lipid droplets occurs.48, 49 Chronic 
combination of hepatic steatosis with low-grade inflammation is defined as nonalcoholic 
steatohepatitis (NASH), which is characterized by hepatocyte damage (e.g., ballooning) with 
or without fibrosis.48, 49 NASH can eventually progress to cirrhosis, liver failure and liver 
cancer, and is an increasing indication for liver transplantation.48, 49 
1.1.2.5 Cell death-inducing DFFA-like effector c 
Among the recently-found targets involved in CMD, growing evidence has shown that lipid-
droplet proteins play a role in the pathophysiology of hepatic steatosis and NAFLD.50-52 Cell 
death-inducing DFFA-like (CIDE) effector c (CIDEC) and its mouse orthologous fat-specific 
protein 27 (Fsp27) belong to the CIDE family and encode for a lipid-droplet-associated 
protein highly expressed in normal condition in white and brown adipose tissues. 
Fsp27/CIDEC is enriched at the sites of contact of two pairing lipid droplets, and promotes 
the fusion of small droplets into larger ones by facilitation of lipid transfer.53 Among the other 
CIDE proteins, CIDEA and CIDEB share similar structure and function, and are highly 
expressed in white adipose tissue and the liver, respectively.54 Fsp27/CIDEC is expressed at 
low levels in normal liver, but highly expressed in the liver of animal models of obesity and 
hepatic steatosis, or following feeding the animals a high-fat diet.50, 55, 56 Hepatocyte-specific 
Fsp27 knockdown in diabetic mice ameliorates hepatic steatosis, whereas hepatocyte-specific 
overexpression induces lipid-droplet synthesis, represses mitochondrial β-oxidation, and 
decreases TG turnover.50 Moreover, partial silencing of Fsp27 with antisense 
oligonucleotides in wildtype or diabetic mice fed chow or high-fat diets has been shown to 
improve insulin sensitivity and whole-body glycemic control,57 and even to reduce 
atherosclerosis in Ldlr-/- mice.58 However, mice with whole-body or adipocyte-specific 
disruption of Fsp27 fed a high-fat diet exhibited increased lipolysis, hepatic steatosis and 
 
 7 
insulin resistance, as consequence of the massive influx of NEFA.59, 60 Hence, only hepatic 
Fsp27/CIDEC should be targeted to prevent adipose tissue lipodystrophy and ectopic lipid 
accumulation. Furthermore, peroxisome proliferator-activated receptor (PPAR) gamma 
(PPARG) was found to control Fsp27 in diabetic mice, as liver-specific ablation of Pparg 
markedly suppressed Fsp27 expression.50 However, in human and mouse liver PPARG is 
expressed at only 10–30% of the levels found in adipose tissue,61 and its expression 
dramatically increases in fatty liver of diabetic mice.62 In addition, various transcriptional 
regulators have been reported to mediate Fsp27/CIDEC expression in the liver, including 
PPAR alpha (PPARA, which seems to control Fsp27/CIDEC expression in normal liver),63 
LXR alpha,64 SREBP1c,65 and several 3’,5’-cyclic adenosine monophosphate (cAMP)-
responsive element-binding proteins (CREBs).66, 67 These intricate regulation networks 
underline the difficulties in identifying new pharmacodynamic targets and the need to deepen 
our knowledge in the field. 
1.1.3 Genetic disposition to cardiometabolic diseases 
As aforementioned, behavioral and metabolic risk factors are the first intervention target for 
ASCVD and CMD. However, also non-modifiable risk factors such as sex, age and genetic 
disposition contribute to the pathophysiology of CMD.2 It is well known that a number of 
mutations in genes involved in cholesterol metabolism, such as LDLR, APOB and proprotein 
convertase subtilisin/kexin type 9 (PCSK9, a posttranslational negative regulator of LDLR in 
the circulation), cause severe hyperlipidemia.4, 68 In addition, several genome-wide 
association (GWAS) studies have identified a plethora of genetic variants considered as risk 
factors for CMD. Among the genes reported to be associated to CMD are for instance 
APOE,69-72 transcription factor 7-like 2 (TCF7L2),73 alpha-ketoglutarate-dependent 
dioxygenase FTO (FTO),74 melanocortin 4 receptor (MC4R),75, 76 and patatin-like 
phospholipase domain-containing 3 (PNPLA3).77 
1.1.4 Differences in liver metabolism between human and mouse 
In the last decades, massive research efforts have been allocated to identifying the 
pathophysiological mechanisms of metabolic disorders and ASCVD. Nonetheless, the results 
gained from preclinical studies using animal models are not always translatable to humans, 
especially due to vast differences in liver metabolism even within mammals.78 Among the 
different vertebrate and invertebrate animal models used in research, mice represent the most 
common model for the phylogenetic closeness to humans, availability, size, easy housing and 
handling, fast reproduction rate, and the fact that they can relatively easily be genetically 
modified by various methods. Different strains of mice, genetically altered or unaltered, have 
been indeed used as translational platforms.45, 79 In addition, sex differences have a great 
impact on the susceptibility to CMD, even in mice with the same genotype.79 
In both humans and mice, the liver is the center of lipid biosynthesis,78 but the two species 
differ in lipoprotein and BA metabolism, in the susceptibility to develop ASCVD/CMD, in 
the response to the most common lipid-lowering drugs (e.g., statins and LXR stimulation), 
and show opposite sex-related differences with respect to hepatic lipid and BA metabolism 
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(e.g., BA synthesis, cholesterol esterification, HDL synthesis). Some of the most important 
differences in cholesterol, lipoprotein and BA metabolism between humans and mice can be 
summarized as follows: 
• plasma cholesterol is mainly transported in LDLs in humans, but in HDLs in rodents; 
• humans have lower rates of cholesterol synthesis and dietary intake, compared with 
mice.45 Moreover, the hepatic clearance of LDLs is higher in mice;45 
• editing of the APOB/Apob mRNA mediated by APOB mRNA editing enzyme 
catalytic subunit 1 (APOBEC1), which produces APOB48 instead of APOB100, 
occurs only in the intestine in humans but also in the liver in rodents;80 
• humans exhibit CETP activity in plasma, conversely to rodents;81, 82 
• humans – but not rodents – express the Lp(a) gene (LPA) in the liver and have 
circulating Lp(a) in plasma;83 
• humans have lower plasma lipolytic activity. LIPC/HL is bound to the endothelium 
membranes in humans, but circulates in the bloodstream in mice.84 Moreover, LPL is 
highly expressed in adipose tissue and heart in both humans and mice, but seems also 
to be produced in the liver by adult mice;85 
• humans express NPC1L1 in the liver and intestine, whereas NPC1L1 is found only in 
the intestine in mice;34 
• the rate of BA synthesis in the liver is lower in humans compared with mice. In 
addition, mouse Cyp7a1 – but not human CYP7A1 – is an LXR-target gene;33, 44, 86 
• humans do not synthesize via the alternative pathway the 6-hydroxylated muricholic 
acids (MCA), which represent instead the largest quota of the mouse BA pool;87-90 
• in humans, amidation with glycine rather than taurine is used to conjugate BAs, 
conversely to mice;33, 86 
• humans cannot rehydroxylate deoxycholic acid (DCA) to CA, in contrast to 
rodents.33, 86 
1.1.5 Mouse and diet models to study cardiometabolic diseases 
Despite the limitations in using animal models to gain insights on human metabolism due to 
major species-specific differences, challenging animal models with high-fat or high-fat/high-
sucrose diet (HFHSD) is frequently used in studies of the pathogenic process leading to 
CMD.91 As a matter of fact, the standard chow diet (5% fat and 0.02% cholesterol in weight) 
does not induce hyperlipidemia in most rodent models used in studies of liver and lipoprotein 
metabolism. C57BL/6 mice, one of the most commonly used mouse strains in animal 
research, carry most of the cholesterol in HDLs and are very efficient in clearing TG-rich 
lipoproteins also when fed a high-fat/low-cholesterol diet. C57BL/6 mice are also resistant to 
develop hyperlipidemia when fed HFHSD,92, 93 but exhibit a mild NASH phenotype after 
around 6 months on this diet.94 Because cholesterol enrichment in the APOB-containing 
lipoproteins is necessary for the atherogenic process, mouse models of atherosclerosis are 
usually genetically modified. For studies of atherosclerosis, mice knocked out for the Ldlr or 
Apoe are commonly challenged with a high-fat/high-cholesterol diet, although Apoe-/- mice 
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do also develop atherosclerosis when fed a chow diet.79 Yet the particles predominantly 
accumulated in the Apoe-/- mice are chylomicrons or VLDL remnants rich in cholesterol and 
containing APOB48,79 thus with little relevance for the human pathophysiology. Apobec1-/- 
and APOB100-only mice produce only APOB100, and attain a human-like profile only on 
the Ldlr-/- background, thus displaying severe hypercholesterolemia.95, 96 CETP-transgenic 
mice exhibit an increase in LDL-cholesterol, or VLDL-cholesterol when bred with Apobec1-/- 
or Ldlr-/-, however without showing a human-like lipoprotein profile.97, 98 It is also worth 
mentioning that adult humans have higher levels of LDL-cholesterol even on a low-fat diet. 
Considering the increase in plasma lipids as a result of dietary challenge, a diet enriched in fat 
is a prerequisite in studies of lipoprotein metabolism and related diseases in most animal 
models, and yet these models show little relevance to the human condition. 
1.2 EMERGING IN VIVO MOUSE MODELS TO STUDY CARDIOMETABOLIC 
DISEASES 
To overcome these limitations, the use of chimeric mice engrafted with human cells 
represented a prominent approach. The generation of these models requires use of immune-
deficient mice and a selective growth advantage for the human cells over the resident ones 
(for review see 99). 
1.2.1 Liver-humanized mice 
In the context of CMD and liver metabolism, the use of chimeric mice harboring human 
hepatocytes designated an important development in models available for preclinical 
research.99 Several liver-humanized mouse (LHM) models have been developed during the 
latest twenty years, all based on the same principle, i.e., a hepatotoxic treatment directed 
against the mouse hepatocytes that allows the repopulation of the engrafted human cells.99 
The first model developed in the 2000s was the albumin-uroplasminogen activator (Alb-uPA) 
transgenic mouse.99, 100 Alb-uPA mice had to be backcrossed on an immune-deficient 
background, such as the severe combined immune deficiency (SCID), in order to enable 
xenotransplantation. Constitutive expression of uPA in the liver induces injury that allows the 
selective expansion of the transplanted mouse or human hepatocytes.99 
Another example is the triple knockout (KO) mouse for fumarylacetoacetate hydrolase 
(Fah), recombination activating gene 2 (Rag2) and interleukin 2 receptor, gamma chain 
(Il2rg), defined as FRG-KO. FRG-KO mice can be efficiently repopulated with human 
hepatocytes, as such or on the nonobese diabetic (NOD)-strain background (FRGN).99, 101, 102 
Rag2 and Il2rg are involved in the development of B and T cells, and natural killer (NK) cells 
respectively. Their KO thus results in impairment of the adaptive immune system.99, 101, 102 
Moreover, backcrossing with the NOD background improves the process of engraftment 
process and the efficiency of the humanization, as the signal-regulatory protein alpha (Sirpa) 
polymorphism contained in the NOD background hinders phagocytosis and production of 
inflammatory cytokines in monocyte-derived macrophages.102-104 When Fah is missing, 
native hepatocytes are continuously damaged by high levels of tyrosine and oxidative stress. 
Prior to transplantation, FRG(N) mice are therefore treated with nitisinone (or NTBC), which 
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is also used in clinical practice to block the upstream tyrosine metabolism and prevent liver 
damage. After transplantation, NTBC is withdrawn to allow selection of the transplanted 
hepatocytes. 
The liver-humanized FRG(N) mouse model has been characterized to a certain extent in 
regard to lipoprotein and BA metabolism, and hepatic zonation and physiology.86, 105-108 After 
transplantation with human hepatocytes, FRG(N) mice display increased LDL and VLDL 
fractions and a lower HDL fraction compared with wildtype mice, thus significantly shifting 
the ratio of LDL-cholesterol to HDL-cholesterol towards a more human-like profile.86 The 
BA profile in bile revealed a human-like pattern as well, with higher ratio of DCA over beta-
MCA, the latter being an exclusive mouse BA.86, 87, 107 However, a more thorough 
characterization of the model is still required to compare their translatability to human 
pathophysiology. 
An extensive comparison among the different LHM models has not been performed yet, but 
each system is likely to present unique advantages or disadvantages for engraftment 
efficiency and downstream applications.99 Nevertheless, LHM are being more commonly 
used for a number of applications, including metabolic and physiological studies, 
personalized medicine, infectious/viral disease, gene therapy, stem cell biology, 
pharmacological and disease modeling.86, 99, 105, 108-112 
1.3 EMERGING IN VITRO/EX VIVO MODELS TO STUDY CARDIOMETABOLIC 
DISEASES 
Preclinical research also utilizes less challenging in vitro/ex vivo models, useful to acquire 
insights and test hypotheses. Furthermore, some of these models can also be used to evaluate 
molecule properties, providing more relevant information compared with the classical clinical 
biomarkers that solely quantify the molecule absolute levels. 
1.3.1 Improved human hepatocyte-like cellular systems 
Primary human hepatocytes (PHH) are regarded as the “gold standard” to study in vitro 
hepatic lipid metabolism and hepatic steatosis/NAFLD. However, these cells present major 
drawbacks such as short lifespan, substantial inter-donor differences, inability to proliferate, 
and loss of transporters and metabolizing enzymes.113 It has also been shown that there is a 
rapid de-differentiation that occurs in PHH cultured under standard monolayer conditions 
(2D), which also affects lipid metabolism.114, 115 Various systems of 3D and/or microfluidic 
culture have been developed to improve the morphology and functionality of PHH.116, 117 In 
parallel, systems with human hepatocyte-like cell lines easier to handle and relatively less 
expensive are being developed. 
1.3.1.1 Culturing with human serum 
Several human hepatocyte-like immortalized cell lines (e.g., HepG2, Huh7 and Huh7.5) have 
been generated, but none of them completely mimic human hepatocytes in vivo under 
standard culturing conditions, i.e., using culturing media supplemented with fetal bovine 
serum (FBS). For instance, HepG2 cells cultured under standard conditions secrete aberrant 
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lipoproteins and display HDL-sized APOB-containing lipoproteins in the cell medium.113 
Culturing media supplemented with 2% human serum (HS) instead of 10% FBS considerably 
improve the usefulness of HepG2 cells to study lipid metabolism.113, 118 HepG2 cells cultured 
with HS display APOB-containing LDL-sized and APOA1-containing HDL-sized particles, 
higher TGs, BAs and PCSK9 levels in the cell medium, and higher beta-oxidation and insulin 
sensitivity.113, 118 These changes are probably secondary to an increased expression of genes 
involved in differentiation and lipid metabolism.113 Thus, this translational model can be used 
in studies of hepatic metabolism and pathology, although a direct functional comparison with 
PHH is required. 
1.3.1.2 Cell genome editing and the CRISPR technology 
Human hepatocyte-like cell lines exhibit multiple chromosomal aberrations that affect gene 
expression and metabolism with respect to hepatocytes in vivo.119-122 For instance, two 
isoforms of SOAT catalyze the formation of intracellular CEs from fatty acids and 
cholesterol: SOAT1, ubiquitously expressed, and SOAT2, which is solely expressed in 
hepatocytes and enterocytes.123 In contrast to SOAT1, SOAT2 determines the amount of CEs 
secreted in APOB-containing lipoproteins, and thereby contributes to the CEs in the 
circulation.124 Moreover, SOAT2 regulates the intracellular levels of CEs and TGs.125, 126 
Conversely to normal hepatocytes in vivo which only express SOAT2, both isoforms are 
expressed in HepG2, Huh7.5 and also in PHH. Hence, KO or editing of genes that alter the 
metabolism of hepatocyte-like cells can improve their phenotype with respect to the in vivo 
situation. 
Since the discovery of the DNA double helix, the possibility of creating site-specific changes 
to the genome of cells and organisms has been contemplating. In the latest years, the genome 
engineering field has profoundly transformed thanks to the clustered regularly interspaced 
short palindromic repeats (CRISPR) technology (for the history of CRISPR development see 
127). The simplicity and versatility of RNA-guided CRISPR programming, together with the 
specific DNA cleaving mechanism, have enabled remarkable developments in genome 
engineering, allowing laboratories around the world to edit genomes of a wide range of cells 
and organisms.127 
The CRISPR technology is based on base-pairing rules between an engineered RNA and the 
target DNA locus. It requires a single guide RNA (gRNA) together with the CRISPR-
associated protein (Cas) enzyme to introduce a site-specific double-stranded break in the 
DNA. The engineered gRNA is characterized by a 20-nucleotide sequence at the 5' side that 
determines binding to the DNA target. The Cas9-mediated cleavage occurs only when a 
PAM (protospacer adjacent motif) signature sequence of 2-6 nucleotides follows the 
sequence of interest on the DNA. The RNA-guided nuclease function is reconstituted in 
mammalian cells through the heterologous expression of RNA components together with 
Cas9.128 After the DNA break, the genome locus becomes substrate for the endogenous 
cellular DNA repair machinery that catalyzes the error-prone non-homologous end joining 
(NHEJ) or the high-fidelity homology-directed repair (HDR). NHEJ gives rise to small 
insertion/deletion (indels) that disrupt the translational reading frame of a coding sequence 
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leading to premature stop codon and ideally a gene KO. Alternately, HDR can be used to 
insert desired sequences or to introduce specific point mutations through recombination of the 
target DNA site with exogenously-supplied DNA templates.129 
A main concern regarding the CRISPR-Cas9-mediated genome editing is the off-target 
events that potentially lead to disruption of other DNA sites than the desired one. A strategy 
combining a mutant nickase version of Cas9 with a pair of gRNAs complementary to 
opposite strands of the target DNA site has been developed in order to improve the 
specificity. This combination allows the DNA break to occur only when both guides induce 
single-stranded nicks at the target region, generating higher specificity and minimizing off-
targets.130 An example of CRISPR strategy is briefly described in 3.2.1. 
1.3.2 Human aortic proteoglycan-binding assay 
High levels of APOB-containing lipoproteins are the most common risk factor for ASCVD 
and CMD,4 and their atherogenicity is explained by the ability to bind to the arterial PG.5, 10 
Particle retention within the arterial wall is indeed the necessary step to their further 
modifications leading to the development of atherosclerosis.131, 132 PG are formed by a protein 
core attached to negatively-charged polysaccharide glycosaminoglycans, which can interact 
with specific positively-charged residues in APOB.10, 131 The composition and size of APOB-
containing lipoproteins (together with the composition and interaction with extracellular PG) 
determine the binding and thus the atherogenicity of the particle.10, 131, 132 Both APOB100 and 
APOB48 can bind PG, although different sites are involved.131, 132 Furthermore, other APOs 
such as APOE show PG-binding sites, which can explain the atherogenicity of entrapped 
APOE-rich remnants, and even mature HDLs.131, 132 It is possible to measure this lipoprotein 
property using PG isolated from human aorta, as described in 3.2.5.5. 
1.3.3 Cholesterol efflux capacity-cellular models 
The increase of plasma HDL-cholesterol levels has been proposed as a potential therapeutic 
strategy to prevent ASCVD and CMD. However, previous GWAS and clinical studies show 
contrasting results.4, 8, 13, 133-135 Thus, as alternative to plasma HDL-cholesterol levels, the 
notion of “HDL functionality” has emerged as the key-determinant for the HDL-mediated 
protection from ASCVD.8 One of the most studied HDL functionality is CEC, i.e., the 
transfer of FC from the intracellular compartment towards an extracellular acceptor, such as 
HDLs.136 It represents one of the initial and most important steps of RCT transport, a process 
by which cholesterol is transferred from peripheral tissues to the liver for subsequent 
elimination in the feces.137 In humans, HDL-CEC has been negatively correlated with both 
intima media thickness and coronary artery disease.138 The composition of HDL subclasses 
appears to be the major determinant of serum CEC,139 which occurs by four mechanisms:140 
active transport mediated by (a) ABCA1 to APOA1 and pre-beta HDLs, and by (b) ABCG1 
to pre-beta and mature HDLs, (c) SRB1-mediated bidirectional efflux to mature HDLs, and 
(d) aqueous diffusion to mature HDLs. 
Several cellular models are used to measure CEC, although there is no common consensus 
about the experimental procedure.141, 142 In general, cells are incubated with labeled 
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cholesterol, equilibrated to distribute the cholesterol equally among the cell pools, treated 
with various compounds (if necessary) and finally incubated with a cholesterol acceptor (e.g., 
serum or isolated lipoproteins) to assess its efflux capacity. 
Aqueous diffusion is a passive transport mechanism driven by a cholesterol concentration 
gradient at the cell membrane. Every cell type is able to passively efflux FC, and murine 
immortalized macrophages such as J774A.1 and RAW 264.7 are most commonly used to 
measure the aqueous diffusion-CEC. When these cells are stimulated with cAMP, Abca1 is 
up-regulated, thus allowing to assess the efflux via ABCA1.143 For the ABCG1 pathway, 
common mammalian lines (such as Chinese hamster ovary cells) overexpressing ABCG1 
have been used, although both the model and the role of this transporter in RCT transport are 
still debated.144-149 Finally, the cell line Fu5AH (rat hepatoma), is commonly used to estimate 
the SRB1-mediated CEC.139, 150 Immunoblot analysis has indeed shown that Fu5AH cells 





2 AIM AND SIGNIFICANCE 
The overall aim of this thesis was to develop and characterize new experimental models 
relevant to the human condition in respect to liver lipid and lipoprotein metabolism, and to 
use these models to validate new therapeutic targets to treat CMD. 
The specific aims in the individual papers were: 
Papers I and II 
To characterize the lipoprotein and liver lipid metabolism in LHM, and the effects of 
HFHSD. Specifically, we focused on assessing liver-related physiological and 
pharmacological species-specific differences between humans and mice, and the variability 
of response among LHM repopulated with hepatocytes from different human donors. 
We also investigated the development of diet-induced CMD in LHM fed a high-fat/high-
fructose/high-cholesterol diet (NASH-diet), and presented these data as preliminary results 
not included in the constituent papers. 
Paper III 
To generate SOAT2-only-HepG2 and SOAT2-only-Huh7.5 hepatocyte-like-cell lines by KO 
of SOAT1 using the CRISPR technology, and to assess the phenotypical changes in lipid 
metabolism when culturing these cells with either FBS or HS. 
Paper IV 
To generate a CIDEC-KO-HepG2 cell model using the CRISPR technology to be used to 
investigate the effects of CIDEC inhibition on human hepatic lipid and carbohydrate 






The results presented in this thesis have been generated using advanced animal models and 
by establishing unique cellular models. Basic and advanced molecular techniques were used 
together with computational biology analyses. A more comprehensive description for every 
experimental procedure can be found in the papers constituting the thesis. 
3.1 EXPERIMENTAL MODELS 
3.1.1 Liver-humanized mice and dietary regimens 
Mice knocked out for Fah, Rag2 and Il2rg (FRG-KO) on the NOD background (FRGN) 
were engrafted with hepatocytes as previously described.101, 102, 104 LHM were transplanted 
with human hepatocytes from different donors, as described in detail in Papers I and II. 
Liver-murinized mice (LMM) are FRGN mice engrafted with NOD mouse hepatocytes and 
served as mouse reference. Both LMM and LHM were fed a maintenance diet (Paper I), 
HFHSD for eight weeks (Paper II), or NASH-diet for eight or twelve weeks. Details on the 
diet composition are provided in Table 3.1. LHM were also treated with the LXR agonist 
GW3965 (30 mg/kg/day) in Paper I. 
 













































Protein 18.9 24.0 22.5 
Table 3.1. Formula composition of maintenance diet, high-fat/high-sucrose diet (HFHSD), and high-
fat/high-fructose/high-cholesterol diet (NASH-diet). Values indicate the approximate weight percentages. 





3.1.2 Human hepatocyte-like cells and culturing conditions 
HepG2 (ATCC) and Huh7.5 cell lines (a kind gift from Prof. Charles M. Rice, The 
Rockefeller University, NY, USA) were cultured at 37 °C and 5% CO2 in Dulbecco Modified 
Eagle Medium (DMEM) supplemented with either 10% FBS or 2% HS, 100 U/mL penicillin, 
and 100 U/mL streptomycin (Thermo Fisher Scientific). The method to culture human 
hepatocyte-like cells with HS was previously described.113 The generated SOAT2-only-
HepG2 and SOAT2-only-Huh7.5 cells were cultured in media supplemented with either FBS 
or HS (Paper III), whereas the CIDEC-KO-HepG2 cells were cultured in medium 
supplemented with FBS (Paper IV). 
3.2 EXPERIMENTAL PROCEDURES 
3.2.1 CRISPR strategy for cell genome editing 
SOAT2-only-HepG2 and SOAT2-only-Huh7.5 cells were generated by KO of the SOAT1 
gene (Paper III), and CIDEC-KO-HepG2 cells were generated by KO of the CIDEC gene 
(Paper IV) following the guidelines provided by Feng Zhang lab.128 In both strategies, 
custom gRNAs for each target were designed in silico. gRNA sequences were cloned into an 
expression plasmid bearing both single gRNA scaffold backbone and Cas9, the endonuclease 
system cleaving DNA. To minimize potential genome off-targets editing, two gRNAs and 
Cas9 nickase were used.130 Transfected cells were then clonally expanded to obtain cell lines 
bearing homogenous mutations in the defined editing sites. Successful biallelic out-of-frame 
editing was detected by Sanger sequencing at KIGene, Karolinska Institutet (Stockholm, 
Sweden). SOAT1 or CIDEC mRNA, protein, or activity levels were assessed in order to 
confirm the functional KO in the edited cells. 
3.2.2 RNA extraction, cDNA synthesis and quantitative real-time PCR 
Total RNA was extracted from snap-frozen organs (Paper I) or cells (Papers III and IV) 
using commercially available spin columns with silica membranes or a phenol-guanidine 
isothiocyanate-based solution. RNA was reverse-transcribed to cDNA with specific kits. 
Quantitative real-time polymerase chain reaction (qPCR) was performed with Fast SYBR 
Green or TaqMan Universal PCR Master Mixes (Thermo Fisher Scientific). The primers used 
in LHM samples were specific for human or mouse orthologous genes (Paper I). Arbitrary 
units were calculated by linearization of the Ct values and normalized to human and mouse 
RNA18S5/Rn18s (18S) rRNA for LHM organs (Paper I) or glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) for human hepatocyte-like cells (Papers III and IV). 
3.2.3 Western blot 
Whole-cell homogenates were prepared from snap-frozen livers (Paper I) or cells (Paper 
III). Equal amounts of protein from individual samples in each group were pooled. To 
perform a titration analysis for the LDLR, different amounts of protein underwent gel 
electrophoresis. Subsequently, proteins were transferred to nitrocellulose membrane and 
blocked before incubation with an antibody against LDLR. Odyssey Fc (LI-COR 
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Biosciences) was used to visualize and quantify the bands. LDLR protein expression was 
quantified by calculation of the first derivative of the linear regression function interpolating 
the titration points for each group pool. 
3.2.4 Enzymatic activity assays 
Plasma lipid transfer activities of CETP and PLTP were assessed in the sera of LMM and 
LHM with fluorometric assays in kinetic measurement (Paper I). SOAT enzymatic activities 
were assessed in microsomes from unedited and SOAT2-only-HepG2 and SOAT2-only-
Huh7.5 cells (Paper III) as previously described.152 
3.2.5 Analysis of lipoprotein metabolism 
3.2.5.1 Quantification of lipoprotein lipids 
Lipoproteins from serum/plasma (Papers I and II) or cell medium (Paper III) were 
separated by size-exclusion chromatography (SEC), and lipids were quantified by real-time 
detection system as previously described.113, 141, 153 
3.2.5.2 Quantification of mediators of lipoprotein metabolism 
Commercially available enzyme-linked immunosorbent assay (ELISA) kits were used to 
assess the levels of CETP, Lp(a) and PCSK9 in serum (Paper I), according to the 
manufacturer’s protocol. APOB, Lp(a) and PCSK9 levels were also assessed in cell medium 
(Paper III). 
3.2.5.3 Apolipoprotein B mRNA editing assay 
To quantify the editing of APOB mRNA in the chimeric livers of LHM (Paper I), we 
developed a qPCR-based assay in collaboration with TATAA Biocenter (Gothenburg, 
Sweden). Two outer primer pairs were designed to specifically amplify APOB in either 
human or mouse cDNA by PCR. Amplicons (or cDNA as such) were analyzed by qPCR with 
inner degenerated primers amplifying both APOB48 and APOB100 transcripts, and two 
probes distinguishing between the two transcripts. A standard curve was established using 
two gBlocks bearing APOB48 and APOB100 variants, respectively. The duplex assay with 
both outer and inner degenerated primers was used to distinguish the editing in either the 
human or mouse component, whereas the inner assay alone with cDNA was used to measure 
the overall sample editing. 
3.2.5.4 Apolipoprotein composition in isolated lipoproteins 
In Paper I, sequential differential micro-ultra-centrifugation in deuterium oxide 
(D2O)/sucrose was used to separate serum lipoproteins, as previously described.154 
Lipoprotein fractions underwent gel electrophoresis to separate APOs and lipoprotein-
associated proteins. Gels were stained with Coomassie G-250 and protein bands were 
identified based on fraction localization and molecular weight. 
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3.2.5.5 Binding to human aortic proteoglycans 
Solid-phase assay was used in Paper I to test serum lipoprotein binding to human aortic PG 
(haPG) isolated from intima-media of human aortas.10, 155, 156 After incubation with haPG, the 
amount of bound cholesterol was quantified and reflects the affinity of the sample for haPG. 
The assay has been standardized to predict the atherogenic potential of serum/plasma or 
isolated lipoproteins. 
3.2.5.6 Cholesterol efflux capacity 
In Paper I, the whole-serum CEC of LHM treated with or without LXR agonist was assessed 
with a radiolabeled cellular assay as previously described.141 J774A.1 cells (ATCC) were 
cultured at 37 °C and 5% CO2 in Roswell Park Memorial Institute (RPMI) 1640 medium 
containing 10% FBS and 50 µg/mL gentamicin (Thermo Fisher Scientific). After plating, 
cells were incubated with [1,2-3H(N)]-cholesterol and an unspecific SOAT inhibitor, 
equilibrated with bovine serum albumin (BSA) to distribute the labelled cholesterol equally 
among the cell pools, and treated with either 8-(4-chlorophenylthio)-cAMP (cpt-cAMP) or 
vehicle. Finally, cells were incubated with or without serum acceptor. Cells incubated without 
acceptor served as baseline for radiolabeled cholesterol. Radioactivity was determined in cell 
lysates or medium by liquid scintillation. The percentage of cholesterol efflux was calculated 
as the ratio of radioactivity in the medium to baseline radioactivity. Aqueous diffusion was 
evaluated by J774A.1 cells cultured under basal conditions, whereas the efflux mediated via 
ABCA1 was the difference between the cholesterol effluxes measured by J774A.1 incubated 
with cpt-cAMP and under basal conditions. 
3.2.6 Analysis of intracellular lipid metabolism 
3.2.6.1 Quantification of intracellular lipids 
Lipids from livers (Papers I and II), cells (Papers III and IV) or portions of the descending 
aorta from LMM and LHM fed a maintenance or NASH-diet were extracted with 
chloroform/methanol 2:1 by volume (also known as Folch extraction) as previously 
described.113, 157 Parts of the extracts were mixed with 1% TritonX-100 and lipids were 
solubilized in water after evaporation of organic solvents. TGs were quantified by a 
colorimetric enzymatic method on the water extracts. In Papers I and II, total cholesterol 
(TC), FC, lathosterol, and lanosterol were analyzed from liver Folch extracts by isotope 
dilution GC–MS.158, 159 Lathosterol and lanosterol are used as biomarkers of cholesterol 
synthesis.160 TC and FC were only quantified in the descending aortas. In Papers III and IV, 
colorimetric enzymatic methods on the water extracts were used to quantify TC and FC. CE 
mass was calculated by subtracting FC from TC and multiplying by 1.67, a conversion factor 
considering the higher molar mass of CEs compared with FC. 
3.2.6.2 Analysis of liver and biliary bile acids 
7alpha-hydroxy-4-cholesten-3-one (C4) is used as a biomarker of BA synthesis, and was 
quantified in liver Folch extracts (Papers I and II) by isotope dilution LC-MS/MS.161 BAs 
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were quantified in livers by LC-MS/MS after extraction with Bile Acids Kit (Biocrates Life 
Sciences)162 (Paper I), and in gallbladders by another LC-MS/MS-based method86, 163 (Paper 
II). 
3.2.6.3 Histological analyses 
Sections of 4 µm were cut on a rotary microtome from paraffin-embedded livers and stained 
with hematoxylin and eosin (H&E) (Paper I). Sections of optimal cutting temperature (OCT) 
compound-embedded hearts from LMM and LHM fed a maintenance or NASH-diet were 
stained with H&E, Oil Red O (ORO), or anti-mouse cluster of differentiation (CD) 68 
antibody conjugate. Sections were visualized with bright-field microscopy. 
3.2.7 RNA sequencing and transcriptomic analysis 
3.2.7.1 Preparation and sequencing of RNA libraries 
In Papers I and II, RNA was extracted from snap-frozen livers and libraries were prepared 
according to the Illumina TruSeq Stranded mRNA Sample Preparation protocol (Illumina). 
All samples showed RNA integrity number (RIN) values above 9.0, and poly(A) selection 
was used to isolate mRNA. After fragmentation, the cDNA strands were synthetized and 
modified to facilitate strand hybridization. DNA products were purified and enriched by 
PCR. RNA libraries were validated using the Bioanalyzer Agilent DNA 1000 (Agilent 
Technologies), pooled and sequenced by Illumina NovaSeq 6000, PE 2x50bp system. 
3.2.7.2 Mapping to human or mouse genome 
The RNA sequencing (RNA-seq) reads were trimmed, filtered and mapped by STAR 
mapper164 to the human genome version GRCh38 and to the mouse genome version 
GRCm38 obtained from Ensembl release 96,165 together with gene annotations (Papers I and 
II). In Paper II, orthologous genes were identified querying Ensembl with biomaRt.166 Gene 
expression was then quantified for each sample (Papers I and II). Principal component 
analysis (PCA) revealed the absence of outliers. 
3.2.7.3 Differential expression analysis 
DESeq2167 in R 3.5.1 was used to assess differentially expressed genes (Papers I and II). 
Logarithmic-fold change was shrank using the Approximate Posterior Estimation for global 
linear models (apeglm) method to improve the estimate of the effect size.168 Wald’s test was 
performed to compare the gene expression in liver samples. In all comparisons, p-values were 
adjusted for multiple testing using the Benjamini-Hochberg method.169 
3.2.7.4 Pathway and Gene Ontology analysis 
Gene Ontology (GO) enrichment pathway analyses were performed using the R library 
gage170 (Paper I) or the enrichGO function of the R library clusterProfiler171 selecting the 
Biological Processes ontology (Paper II). 
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3.3 STATISTICAL ANALYSIS 
In Papers I and II, the robust regression and outlier removal (ROUT) method (Q = 5%) was 
performed prospectively to remove group outliers. Data from pooled samples and lipoprotein 
chromatograms are expressed as mean, ± standard error of the mean (SEM) when indicated. 
Spearman rank correlation analysis (Paper I) or Pearson correlation coefficient (Paper II) 
were used to determine associations between continuous parameters. Statistical significance 
was set to α < 0.05, unless otherwise stated. All statistical analyses and graphs were 
performed using Statistica (TIBCO Software Inc.) and GraphPad Prism (GraphPad Software, 
Inc.). For transcriptomic analysis, see 3.2.7. 
In Paper I, a nonparametric analysis was used. Data are expressed as medians and 
interquartile range or scattered dots. Significant differences among groups were tested using 
Kruskal-Wallis test followed by Dunn’s multiple comparison test. After Holm-Bonferroni 
adjustment, statistical significance was set at the level of α < 0.01 (α < 0.05 for post hoc 
analyses). In the LXR study the α-value was kept to 0.05, and Mann-Whitney U test was used 
to compare two groups. 
In Paper II, all data were analyzed after log-transformation to reduce intragroup variability. 
Normality was tested for all variables by Shapiro-Wilk W test before comparing the groups 
using a parametric analysis. Data are presented as means of scattered dots or ± SEM. One-
way analysis of variance (ANOVA) followed by post hoc comparison using Tukey honestly 
significant difference (HSD) test were used for contrast among the groups. 
In Papers III and IV, data from individual wells or flasks are expressed as means ± SEM or 
scattered dots. One-way ANOVA and Tukey HSD post hoc test were used to compare 
multiple groups. Significant differences between two groups were tested by unpaired two-
tailed t test. 
Data from LMM and LHM fed a maintenance or NASH-diet for eight or twelve weeks are 
presented as scattered dots with means represented by bars. To assess the effects of liver 
humanization, dietary regimen and dietary feeding time, significant differences were tested 
by factorial ANOVA. Data were log-transformed to stabilize variances. 
3.4 ETHICAL CONSIDERATIONS 
The correctness of research with animal models and humans is controlled by ethical review 
committees, which set the principles of good research practice considering its wider 
consequences. The animal studies presented in this thesis were approved by the appropriate 
ethical authority as indicated: DN000024; 2010/678-31/3; S82-13; 2017/269-31; LREC 01-
016. Research efforts worldwide strive to gain a better understanding of the 
pathophysiological mechanisms underlying several morbidities in order to prevent disease 
diffusion, discover new therapies, and to ultimately improve the quality of our lives. Before 
new discoveries are tested in humans, various models in preclinical and clinical research 
settings are used to assess research hypotheses and perform toxicology studies, such as 
human-derived cells or tissues and animals. However, the use of these models is known to 
represent an ethical dilemma for multiple reasons, including their relevance to the human 
condition, an aspect that unfortunately seems to be largely underestimated. 
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3.4.1 Reflections from Papers I and II 
The studies with LHM allowed to deepen the considerations on the human translatability of 
animal models in preclinical research. Moreover, because LHM receive cells from human 
donors, they also entail important reflections on the possibility to perform personalized 
studies and on the protection of the personal data gained. 
Extensive mechanistic studies on multifactorial diseases involving several organs (such as 
CMD) cannot be performed in regular cellular models due to major limitations, nor in 
humans unless proven hypotheses are obtained in animal models. However, differences 
among the species limit the translatability of animal models to the human condition, as 
widely discussed. LHM were chosen as the central model within the EU-FP7 project 
HUMAN (Health and the Understanding of Metabolism, Aging and Nutrition), which aimed 
to study the effects of genetic and dietary factors involved in the development of human 
CMD in humanized mouse models. The validation of preclinical models with improved 
human relevance provides the possibility to dramatically reduce the number of animals used 
in research. This is in accordance with the principle of the 3Rs, which represents a framework 
for conducting high-quality research with the aim to develop alternative approaches to avoid 
the animal use: Replace (in vitro using cellular models), Refine (considerations on animal 
welfare) and Reduce (use the minimal number of animals sufficient for statistical analysis). 
As also indicated within the HUMAN research project, “There must be a balance between the 
objectives of the research and the means used.” 
The PHH used to repopulate LHM can be selected from cryopreserved biobanks based on 
genotype, age and clinical/metabolic data. Because LHM can reproduce traits of the original 
phenotype,108-110 human donors can theoretically be recalled for additional testing based on 
the data obtained from LHM. This potential application of personalized medicine represents 
another ethical justification for the use of humanized animal models. 
Moreover, all partners within HUMAN had to follow international guidelines and ethical 
rules for human samples (Declaration of Helsinki), information about the donors and animal 
experimentation. In fact, the project involved patients, healthy volunteers, human genetic and 
biological samples, and collection of data where subjects are identified with a study-ID 
number. The processing of this sensitive information (e.g., health status or ethnicity) had to 
be carried out in accordance with the General Data Protection Regulation (GDPR) and thus 
preventing tracking by external parties. 
3.4.2 Reflections from Papers III and IV 
If the intrinsic species differences of the animal models represent a major limitation, the use 
of cellular models entails likewise problems for their clinical translatability. In fact, 
immortalized cell lines derive from tissues and cells carrying severe diseases, and their 
genetic instability affects their metabolism with respect to the original tissue. Similarly, 
primary cells can easily undergo phenotype changes once removed from the original tissue, 
and their culturing is cumbersome due to limited proliferative capacity and short lifespan. 
Hence, the development of immortalized cellular models better representing the physiological 
situation of cells in vivo is a necessary step to improve the human relevance of in vitro 
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models for preclinical studies, and also to reduce the number of animal studies. 
HepG2 and Huh7.5 are human hepatocyte-like immortalized cells derived from human 
hepatoblastoma and hepatocellular carcinoma, respectively.172, 173 Such cell lines can 
proliferate indefinitely and are routinely used in preclinical research. Moreover, they do not 
require an ethical approval, as they do not present neither developmental potency nor 
possibility to cross-contaminate human subjects. Although the use of genome-editing 
techniques such as CRISPR raises strong ethical controversy for their potential application in 
humans and human embryonic stem cells, genome editing is allowed in cells lines, and can be 
used to KO genes that impair their phenotype. This possibility represents a great opportunity 
to improve cellular models. In addition, culturing human hepatocyte-like cells in media 
supplemented with 2% HS was shown to greatly improve their functionality and usefulness in 
metabolic studies.113 Altogether, these improvements provide a better model to study in vivo 
hepatocyte metabolism. Of note, the use of human blood (commercially available) does not 




4 RESULTS AND DISCUSSION 
4.1 A HUMANIZED LIPOPROTEIN AND LIVER METABOLISM IN LIVER-
HUMANIZED MICE 
4.1.1 Liver-humanized mice exhibit a human-like lipoprotein profile similar 
to the human donor 
The main part of the cholesterol transported in the bloodstream is carried in LDL particles in 
humans and in HDL particles in mice. LHM were shown to display a typical human-like 
distribution of plasma cholesterol, shifting the cholesterol transport into LDL rather than 
HDL particles.86 In Papers I and II, we widened this observation by finding that the 
humanization of the cholesterol lipoprotein profile depends on the hepatocytes of the human 
donor. As shown in Figure 4.1, distinct and donor-specific cholesterol lipoprotein profiles 
were consistently found in various groups of LHM engrafted with human hepatocytes from 
different donors. The intriguing idea that LHM can recapitulate the metabolic features of the 
human donor has already been proposed in previous studies.108-110 Further insight came from 
the comparison of the lipoprotein profiles of the human donor A with those of the LHM 
engrafted with the PHH from this donor (LHM-A) and LMM (Figure 4.1A). Human donor A 
and LHM-A displayed similar – but not identical – cholesterol lipoprotein profiles, 
conversely to the typical mouse distribution found in LMM. Likely, the minimal residual 
activity of the mouse liver, the interaction between the tissues of the mouse recipient and the 
human donor, and the mouse peripheral metabolism prevent the achievement of identical 
lipoprotein profiles. 
4.1.2 Circulating APOB100 and hepatic LDLR (but not CETP) determine the 
humanization of the lipoprotein profile 
In Paper I, we extended the investigation on the species-specific differences between human 
and mice in liver metabolism responsible for the humanization of the lipoprotein profile. 
Among these (see 1.1.4), CETP is a plasma lipid transfer protein expressed in humans but not 
in mice. CETP promotes the equimolar exchange of CEs contained in HDLs for TGs from 
VLDL and LDL particles. Thus, its presence in humans is considered one of the main 
mechanisms in determining the higher amount of plasma cholesterol carried in APOB-
containing lipoproteins.81, 82 Humans express CETP predominantly in the spleen, adipose 
tissue and liver, hence we sought to assess whether LHM expressed CETP in the liver. We 
analyzed the CETP expression at mRNA and protein level in the liver, and CETP protein and 
activity in the circulation, but we were unable to detect it neither in the liver nor in the blood 
(Paper I). The hepatic expression of CETP in humans is driven by macrophage-resident 
Kupffer cells.174 This explains the absence of CETP in LHM, which are only engrafted with 
human hepatocytes and, consequently, have resident mouse Kupffer cells in the chimeric 
livers. Therefore, the humanization of the lipoprotein profile in LHM is not dependent of 
CETP. In humans, CETP homozygous loss-of-function mutations are often associated with 
hyperalphalipoproteinemia, i.e., an excess of HDL- over LDL-cholesterol.175, 176 This 
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suggests that CETP in humans plays an extremely important role in regulating the 
homeostasis of plasma cholesterol, and that further physiological mechanisms underlie the 
different distribution of plasma cholesterol in humans and mice. 
 
 
Figure 4.1 The human-like cholesterol lipoprotein profile in LHM depends on the hepatocytes of the 
human donor. Lipoproteins were separated by SEC and cholesterol was quantified. (A) Cholesterol profile of 
human donor A, of the LHM engrafted with the PHH from this donor (LHM-A), and of LMM. Cholesterol profiles 
of LHM transplanted with F1 (B), F2 (C), M1 (D), or M2 (E) hepatocytes. Profiles represent the mean 
chromatograms, and the shaded area around them represents the SEM. From Paper I. 
 
We then hypothesized that the predominant distribution of cholesterol in LDL particles 
resulted from higher levels of circulating APOB100, as lipoproteins containing APOB100 
rather than APOB48 have higher half-life in the circulation.177 Among other interspecies 
differences in liver and lipoprotein metabolism, humans do not edit APOB mRNA in the 
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liver, thereby producing only APOB100.80 Moreover, humans have lower hepatic LDL 
clearance compared with mice.45 As shown in Figures 4.2A and 4.2C respectively, the editing 
of APOB mRNA and the expression of LDLR in the liver of LHM were approximately 70% 
lower compared with LMM. Furthermore, LHM exhibited higher levels of PCSK9 (Figure 
4.2D), a posttranslational negative regulator of LDLR in the circulation.4 Altogether, these 
changes synergistically increase the levels of APOB100 in the circulation of LHM (Figure 
4.2B), thereby conferring increased half-life on VLDLs and LDLs.177 Finally, the lipoproteins 
of LHM displayed binding to haPG and plasma lipid levels similar to normal physiological 
values in humans (Paper I). These results corroborate LHM as a clinically translatable model 
for studies of lipoprotein metabolism and atherosclerosis. 
 
 
Figure 4.2. Higher levels of APOB100 in the circulation and lower LDLR expression in the liver 
determine the humanization of the lipoprotein profile in LHM. (A) APOB mRNA editing quantified in liver 
by a qPCR–based assay. Lines indicate the medians of scattered dots. Mann-Whitney U Test; ** p < 0.01. (B) 
APO composition of LDLs and HDLs. Serum lipoproteins were isolated and underwent gel electrophoresis 
before staining. (C) LDLR protein expression in the liver by Western blot. Data are presented as mean and 
SEM. (D) Human and mouse PCSK9 in the circulation quantified by ELISA. Lines indicate the medians of 
scattered dots. Kruskal-Wallis test followed by multiple comparisons; * p < 0.05. Abbreviations: SAA, serum 
amyloid A. From Paper I. 
 
4.1.3 Liver-humanized mice are resistant to a high-fat/high-sucrose diet 
Conversely to conventional mouse models, LHM fed a maintenance diet appeared to be a 
translatable model to study human hepatic and lipoprotein metabolism (Paper I). Therefore, 
in Paper II we aimed to test whether the feeding of LHM a HFHSD, consisting of 24% fat 
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and 20% sucrose, for eight weeks could impair the lipid phenotype of these mice. We 
considered eight weeks to be enough to see pathological effects without impairing cell 
survival and liver inflammation. The analysis of plasma lipids in LHM fed HFHSD 
confirmed higher levels of cholesterol and TGs in the APOB-containing lipoproteins, but 
plasma levels of TC did not significantly differ to LMM after HFHSD (Paper II). Moreover, 
plasma levels of TC and TGs were similar between LHM fed a maintenance diet or a HFHSD 
(Papers I and II). These data indicate that LHM as well are resistant to the development of 
hyperlipidemia after lipid and carbohydrate challenge, as seen in several conventional mouse 
models. 
Considering the resistance to HFHSD, we could use the data from Paper II to infer further 
differences in liver lipid metabolism between LMM and LHM, thanks also to the 
transcriptomic analysis to investigate differences in gene expression underlying the metabolic 
phenotype. LHM fed a HFHSD exhibited significantly lower levels of HDL-cholesterol 
compared with LMM, as observed also on the maintenance diet (Paper I). In mice, the 
hepatic expression of Abca1 is the major determinant for circulating HDLs.24 Analysis of the 
liver transcriptome revealed ABCA1 together with several genes involved in the synthesis, 
maturation and the structure of HDLs to be downregulated in LHM compared with LMM 
(Paper II). Because the transfer of cholesterol from HDLs to APOB-containing lipoproteins 
mediated by CETP is absent both in LMM and LHM (Paper I), the lower levels of 
cholesterol circulating in the HDL fraction of LHM seem to stem from the reduced hepatic 
expression of several HDL-associated genes. 
Further confirmation for the resistance of LHM to HFHSD came from the analysis of the 
liver lipids. Overall, both hepatic TG and TC levels were similar between LMM and LHM 
(Paper II). However, LHM exhibited higher plasma levels of TGs compared with LMM 
(Paper II) The expression of genes associated with TG synthesis, mobilization, and secretion 
were upregulated, whereas genes important for plasma lipolysis and TG uptake (e.g., LPL 
and LIPC/HL) were downregulated in the liver of LHM (Paper II). These results suggest that 
an increase in hepatic TG synthesis and secretion, and a decreased lipolysis in plasma seem to 
underlie the higher levels of plasma TGs in LHM. 
Hepatic cholesterol metabolism is discussed more in detail in 4.1.5. 
4.1.4 Liver-humanized mice develop atherosclerosis on a NASH-diet 
High plasma levels of APOB-containing lipoproteins are a prerequisite for atherogenesis. 
However, the resistance of LHM to HFHSD hinder their use for studies of CMD. This was 
seen also in another strain of LHM, that did not develop atherosclerosis after ten weeks of 
feeding a high-fat diet with 0.3% cholesterol.178 Hence, we fed LMM and LHM a NASH-diet 
consisting of 21% fat, 22% fructose and 2% cholesterol for eight or twelve weeks which 
previously has been shown to induce NASH, insulin resistance and oxidative stress in other 
rodent models.179, 180 LHM fed NASH-diet had higher body weight and liver-to-body weight 
compared to LHM fed a maintenance diet.181 Moreover, liver histology revealed hepatic 
steatosis at week 8, and hepatocyte ballooning and fibrosis at week 12.181 The quantification 
of plasma lipids is shown in Figure 4.3. Both after eight and twelve weeks, LHM fed NASH-
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diet exhibited a dramatic increase in plasma TC, remnant cholesterol, LDL-cholesterol and 




Figure 4.3. Plasma lipids dramatically increase in LHM fed a NASH-diet. LMM and LHM-F4 were fed 
maintenance or NASH-diet for 8 or 12 weeks. Lipids were quantified in plasma by routine clinical assays. Bars 
represent the means of scattered dots. When present, grey areas indicate the values outside the human 
physiological range. Data were log-transformed before factorial ANOVA using liver humanization (donor), 
dietary regimen (diet) and dietary feeding time as factors. Because dietary feeding time did not significantly 
differ in any comparison, the p-values for donor, diet and their interaction are only reported. Abbreviations: 
NEFA, non-esterified fatty acids. 
 
To investigate whether the distorted lipid phenotype also resulted in the development of 
atherosclerosis, we analyzed the cholesterol content in the aorta (Figure 4.4). Despite similar 
levels of TC and FC in LHM and LMM regardless of the dietary regimen, LHM fed NASH-
diet exhibited higher levels of CEs in the aortas, which reflect the formation of atherosclerotic 
plaques.182 The development of atherosclerosis in LHM after NASH-diet was confirmed by 
histological analysis of the aortic valve/bulb, and was more evident in the 12-week group. As 
shown in Figure 4.5, aortic walls were thicker due to lipid accumulation (panels A and B), 
and were also enriched of cells positive for CD68 (panel C), indicating macrophage/foam cell 





Figure 4.4. LHM fed a NASH-diet accumulate CEs in the descending aorta. LMM and LHM-F4 were fed 
maintenance or NASH-diet for 8 or 12 weeks. TC and FC in aortas were quantified by isotope dilution GC–MS 
after Folch extraction. CEs were calculated as (TC - FC) x 1.67. Bars represent the means of scattered dots. 
Data were log-transformed before factorial ANOVA using liver humanization (donor), dietary regimen (diet) and 
dietary feeding time as factors. Because dietary feeding time did not significantly differ in any comparison, the 
p-values for donor, diet and their interaction are only reported. 
 
 
Figure 4.5. LHM develop atherosclerosis on a NASH-diet. LMM and LHM-F4 were fed maintenance or 
NASH-diet for 8 or 12 weeks. Hearts were embedded in OCT compound and slices were stained. 
Representative images for the aortic valve/bulb from one mouse per group are shown (magnification 10X) (A) 
Morphology after H&E stain. (B) Lipid accumulation after ORO stain. (C) CD68-positive cells. 
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From these experiments, it is possible to deduce interesting conclusions on the atherogenic 
process in LHM. First, LHM develop atherosclerosis despite the absence of CETP, as the 
regular mouse models for atherosclerosis. This entails that LDL-cholesterol, and especially 
CEs, drive the atherogenesis independently of the source, and that the beneficial effects of 
lowering LDL-cholesterol may depend on the corresponding reduction in APOB-containing 
lipoproteins.183 Secondly, the atherosclerotic lesions in LHM seem to progress regardless of 
their absent adaptive immune system, as KO of Rag2 and Il2rg prevents the development of 
B, T and NK cells.101, 102 Lymphocytes are considered important for the lesion progression 
already in the early stages, by secreting both pro- and anti-atherogenic cytokines, and 
ultimately exacerbating the inflammation of the arterial wall.5, 184, 185 In LHM, CD68-positive 
cells (macrophages, but also smooth muscle cells that can take up lipids, turning into foam 
cells) seem sufficient to drive the atherosclerosis progression. Taken together, these 
considerations highlight the importance and the causative role of APOB-containing 
lipoproteins (in particular LDL particles) and of the deposition of cholesterol within the 
endothelium (triggering the innate immune response) in the development of atherosclerosis, 
as already stated.4, 11, 12 
4.1.5 Bile acid metabolism is human-like yet altered in liver-humanized mice 
As described in 1.1.4, several differences in BA metabolism are present between humans and 
mice. LHM fed a HFHSD exhibited a humanized biliary BA composition (Paper II and 
Figure 4.6), similarly to what was observed in LHM under maintenance diet.86, 107 Again, the 
similar results regardless of the dietary regimen corroborate the resistance of LHM to 
HFHSD. The molar fraction of glycine-conjugated BAs – which is low in mice – was 
significantly higher in LHM compared with LMM. Moreover, the proportion of tauro-DCA 
was more than double in LHM, in line with the inability of human hepatocytes to reconvert 
DCA to CA. Finally, the levels of taurine-conjugated MCA – highly represented in LMM – 
were dramatically reduced in LHM. It has been shown that deletion of Cyp2c70 in mice 
virtually inhibits the synthesis of MCA.88-90 Intriguingly, Cyp2c70-/- mice exhibited lower 
synthesis of BAs and cholesterol, as well as lower levels of LDLR in the liver resulting in an 
increase of plasma LDL-cholesterol.90 Although the levels of VLDL- and LDL-cholesterol 
doubled compared with wildtype mice,90 this was not sufficient to determine a full 
humanization of the cholesterol lipoprotein profile as in LHM, presumably due to the 
maintained ability of the mouse liver to edit APOB mRNA. Nevertheless, these results 
suggest that MCA in mice play a major role for several differences in liver and lipoprotein 
metabolism compared with humans, and that a reduction of MCA in LHM may contribute to 
the humanization of their metabolic phenotype. Further investigations are needed to verify 
whether these effects are due to inhibition of the hepatic FXR signaling or to other 
unidentified mechanisms.88-90 
Lower rates of cholesterol synthesis and dietary intake in humans compared with mice 
translate into lower rates of BA synthesis in the liver;33, 45 hence, LHM were expected to have 
reduced BA synthesis. This was not the case, as LHM were found to have higher hepatic 
expression of genes involved in BA synthesis compared with humans,86 and higher levels of 
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C4, a biomarker for BA synthesis, compared with LMM (Paper II). The explanation for the 
increased BA synthesis in LHM relies on the unresponsiveness of human hepatocytes to the 
murine intestinal FGF15, which results in abnormal enterohepatic signaling and hepatic BA 
metabolism, as previously reported.86, 105, 107 
 
 
Figure 4.6. Biliary BA composition is humanized in LHM. BAs were extracted from the emptied 
gallbladders of LMM, LHM-F3 and LHM-C186, and measured by LC-MS/MS. Mole fractions were calculated, 
and data are presented as mean and SEM. Data were log-transformed before one-way ANOVA followed by 
Tukey HSD test. * p<0.05, ** p<0.01 and *** p<0.001. G- and T- indicate the glycine- and taurine-conjugates 
respectively. Abbreviations: CA, cholic acid; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; LCA, 
lithocholic acid; UDCA, ursodeoxycholic acid; MCA, muricholic acid. From Paper II. 
 
As discussed in 4.1.3, the levels of TC in the liver did not significantly differ between LHM 
and LMM on HFHSD, and this was valid also for hepatic CE levels (Paper II). However, 
hepatic levels of CEs only correlated with hepatic TGs and plasma cholesterol levels in LMM 
(Paper II), suggesting a dissociation of CEs from hepatic TG storage and cholesterol 
secretion occurring in LHM. This is likely resulting from the increased BA synthesis, which 
led to a higher utilization of cholesterol. The transcriptomic analysis revealed genes important 
for BA synthesis, uptake, and export to be upregulated in LHM compared with LMM (Paper 
II), including NPC1L1, thought to be involved in the uptake of cholesterol from the bile in 
human – but not in mouse – hepatocytes.34, 35 The increased BA synthesis in LHM was also 
accompanied by an increase in lathosterol (Paper II), reflecting sustained cholesterol 
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synthesis. Hence, the correlation between cholesterol and BA biosynthesis observed in LHM 
suggests that BA synthesis in this model seems to rely more on the newly synthetized 
cholesterol, the CE pool, and the uptake of cholesterol from the bile, rather than uptake of 
cholesterol from plasma. In line with this conclusion is the downregulation of the expression 
of hepatic SOAT2, LDLR, and LRP1 observed in LHM compared with LMM (Paper II). The 
positive correlation between cholesterol synthesis and BA synthesis does not normally occurs 
in humans.35, 186, 187 This correlation only occurs when the enterohepatic circulation of BAs is 
interrupted as in patients with bile fistula, in which inhibition of cholesterol synthesis leads to 
a decrease in BA synthesis.188 Therefore, LHM seem to resemble the condition of humans 
having an interrupted enterohepatic circulation of BAs, in line with the unresponsiveness of 
human hepatocytes to murine FGF15. 
The altered BA synthesis resulting from the interrupted BA signaling may also explain – at 
least in part – the resistance of LHM to HFHSD. While the HFHSD used in this study was 
low in cholesterol, the NASH-diet with 2% cholesterol prompted LHM to develop severe 
hepatic steatosis and atherosclerosis. This suggests that high levels of exogenous cholesterol 
are necessary to overcome the aberrant synthesis of BAs and to induce the development of 
CMD. 
4.1.6 Liver-humanized mice predict human liver pharmacodynamics: the 
LXR study 
After we demonstrated the humanization of lipoprotein and liver lipid metabolism in LHM, 
we sought to explore the possibility of this model to predict the pharmacodynamic properties 
of human liver. As a proof of concept, we aimed to test the pharmacological stimulation of 
the LXR system in LHM (Paper I), a strategy considered to have great potential to decrease 
hyperlipidemia and atherosclerosis.43 The LXR system has indeed important functions in 
regulating cholesterol and fatty acid metabolism, and inflammation.43 Preclinical studies 
aiming to understand the effects of LXR stimulation showed contrasting results: LXR 
stimulation was proven to be antiatherogenic in C57BL/6, Ldlr-/- and Apoe-/- mice,189, 190 but 
to increase LDL-cholesterol in hamsters and cynomolgus monkeys, which express the LXR-
target gene CETP.191 As expected, the clinical trial testing the effects of the LXR agonist 
BMS-852927 was prematurely terminated after severe combined hyperlipidemia and TG 
accumulation in the liver.192 As shown in Paper I, the levels of plasma cholesterol and TG 
levels (especially in the APOB-containing lipoproteins) dramatically increased in LHM 
treated with 30 mg/kg/day of the LXR agonist GW3965 for three days. Despite the lack of 
CETP, LHM recapitulated the hyperlipidemia observed in humans,192 and could be used to 
elucidate further (and unexpected) negative effects on liver lipid metabolism after LXR 
stimulation, as outlined in Figure 4.7. 
Conversely to rodents, the LXR-dependent increase of BA synthesis via hepatic CYP7A1 is 
absent in humans, hamsters and cynomolgus monkeys.44, 191 LXR stimulation in LHM 
actually led to a dramatic decrease of CYP7A1 mRNA expression and of the classical 
pathway of BA synthesis (assessed by liver C4 and BA levels), secondary to the upregulation 
of nuclear receptor subfamily 0 group B member 2 (NR0B2, also known as small heterodimer 
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partner, SHP) and FGF19 (Paper I). As a result, cholesterol accumulated in the liver, and 
decreased the levels of sterol regulatory element-binding transcription factor (SREBF) 2 and 
its target genes, e.g., HMGCR and LDLR. The downregulation of cholesterol synthesis was 
confirmed by the reduced levels of hepatic lathosterol and lanosterol (Paper I). The excess of 
hepatic cholesterol was converted in CEs, that accumulated within the liver (Paper I). Liver 
TGs were also increased in LHM after treatment with GW3965, and moderate 
macrovesicular steatosis was evident from the histological analysis of the liver (Paper I). The 
hepatic TG accumulation in the liver of LHM treated with GW3965 appeared to be mediated 
by an upregulation of lipid-droplet associated genes (i.e., perilipin 2 and CIDEC) and reduced 
hydrolysis of CEs and TGs. The elevated levels of TGs and CEs in the liver led to increased 
secretion of cholesterol-rich VLDLs, whereas the increase in plasma TGs (especially in the 
LDL fraction) seems to derive from a lower LIPC/HL-mediated hydrolysis. 
 
 
Figure 4.7. The decrease in neutral lipid hydrolysis and BA synthesis explains the increased 
intracellular and plasma lipids after LXR stimulation in human hepatocytes. Red, black and blue arrows 
indicate decrease, no change and increase, respectively. From Paper I. 
 
One consideration has to be made on the lipogenic effects of LXR stimulation and on the 
specificity of the agonist used. The BMS-852927 agonist used in the clinical trial was 
selective for LXR beta, and was developed to avoid the lipogenic properties of pan-LXR 
agonists mainly ascribed to hepatic LXR alpha activation from different studies in KO 
mice.43, 191, 192 Nevertheless, elevation of plasma and liver TG levels was evident in human 
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subjects, and similar results were found in LHM treated with the pan-LXR agonist GW3965. 
These results suggest that LXR beta stimulation is sufficient to exert lipogenic effects in 
human liver. Moreover, upregulation of hepatic SREBF1 variant c (a well-known LXR-target 
gene) in LHM did not affect the target genes involved in de novo lipogenesis, indicating the 
presence of further human-specific mechanisms that were not identified in preclinical studies 
using conventional mouse models. 
Finally, another aspect to consider is the increase of serum CEC by aqueous diffusion and 
ABCA1 found in LHM after LXR stimulation (Paper I), which represents the increased 
ability of all serum components (i.e., lipoproteins, APOs and albumin) to accept cholesterol 
from tissues via certain mechanisms. Although the increase of CEC has been considered as 
one of the main atheroprotective properties of LXR stimulation (especially when referred to 
HDLs), this effect in humans may be dampened by the unfavorable lipoprotein and liver lipid 
phenotype. 
4.2 HOW TO IMPROVE THE HUMAN RELEVANCE OF LIPOPROTEIN AND 
INTRACELLULAR METABOLISM IN HEPATOCYTE-LIKE CELL LINES 
4.2.1 Culturing with human serum 
HepG2 and Huh7.5 are two human hepatocyte-like cell lines derived from human 
hepatoblastoma and hepatocellular carcinoma, respectively.172, 173 HepG2 cells have long 
been used as a preclinical model for studies of hepatic lipid metabolism, whereas Huh7.5 
cells have more recently been used for these studies and are thus less well characterized. 
However, both cell lines exhibit major differences compared with human hepatocytes in vivo 
that limit their relevance for studies on human pathophysiology. For instance, HepG2 cells 
cultured under standard conditions with 10% FBS secrete aberrant lipoproteins and display 
HDL-sized APOB-containing lipoproteins in the cell medium.113 Hence, it is necessary to 
explore and validate new strategies to improve the usefulness of hepatocyte-like cellular 
models for studies of hepatic lipid metabolism. Culturing of HepG2 cells in medium 
supplemented with 2% HS instead of 10% FBS increased the levels of APOB-containing 
LDL-sized and APOA1-containing HDL-sized particles, tremendously improving the lipid 
phenotype of HepG2 cells.113 As we and others previously found Huh7.5 cells to have higher 
levels of intracellular TGs,193, 194 and thus have the potential to be better suited as model for 
hepatic steatosis/NAFLD, as well as to better characterize this cell line, in Paper III we also 
assessed the effects of culturing Huh7.5 with FBS and HS. Supplementation of the culturing 
medium with HS did not improve the lipoprotein phenotype of Huh7.5, as lower levels of 
cholesterol in the medium were found compared with cells cultured with FBS (Paper III). 
Similarly, the levels of TGs secreted in the medium (especially in the LDL fraction) increased 
in HepG2 cells cultured in HS,113 but were lower in Huh7.5 cells compared with cells 
cultured with FBS (Paper III). In line with these results, HepG2 cells cultured in medium 
supplemented with HS had higher levels of APOB in the medium,113 but no changes were 
found in Huh7.5 cells compared with cells cultured with FBS (Paper III). Culturing with HS 
resulted in decreased levels of intracellular FC, CEs and TGs in both cell lines (Paper III). 
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This is particularly important in HepG2 cells, as an impaired intracellular lipid mobilization 
appears to be responsible for the secretion of smaller APOB-containing lipoproteins.113 
However, the most evident effect on the levels of intracellular TGs was observed in Huh7.5 
cells, in which intracellular TG levels decreased by about 75% and thereby reached similar 
levels as observed in HepG2 cells, although this was not associated with an improved 
lipoprotein profile. Finally, supplementation of the culturing medium with HS restored the 
levels of BAs in the medium in HepG2 cells,113 whereas BA levels were too low to be 
accurately detected in Huh7.5, regardless of the supplementation of the culturing media 
(Paper III). The improvements observed in HepG2 cells cultured with HS are likely 
dependent on the increased expression of important genes of lipid metabolism and hepatocyte 
differentiation.113 These results highlight the importance of both the culturing conditions and 
the cell line utilized as in vitro model for human pathophysiology. Collectively, these 
findings suggest HepG2 cells cultured in HS to better reflect the physiological condition of 
human hepatocytes in vivo. Conversely, culturing of Huh7.5 cells under standard conditions, 
or potentially in media supplemented with exogenous lipids,118 may be better suited for 
studies of hepatic steatosis/NAFLD.  
4.2.2 Genome editing 
4.2.2.1 Knockout of sterol O-acyltransferase 1 
Because impaired intracellular lipid mobilization is associated with lower secretion of APOB-
containing lipoproteins, we sought to improve this aspect in HepG2 and Huh7.5 cells. As 
described in 1.3.1.2, two isoforms of SOAT catalyze the formation of intracellular CEs from 
fatty acids and cholesterol: SOAT1, ubiquitously expressed, and SOAT2, which is solely 
expressed in hepatocytes and enterocytes, and determines the amount of CEs secreted in 
APOB-containing lipoproteins.123, 124 Conversely to normal hepatocytes in vivo, which only 
express SOAT2, both isoforms are expressed in HepG2, Huh7.5 and also in PHH. Because 
the presence of SOAT1 in hepatocyte-like cell lines may contribute to their distorted 
lipoprotein and lipid phenotype, in Paper III we used the CRISPR technology to KO SOAT1 
in HepG2 and Huh7.5 cells, generating models better resembling the situation of human 
hepatocytes in vivo expressing only SOAT2. Moreover, we cultured both unedited and 
SOAT2-only cells with either FBS or HS to assess whether the combination of SOAT1-KO 
with culturing with HS could further improve the phenotype of HepG2 and Huh7.5 cells. 
SOAT2-only-HepG2 cells exhibited even higher levels of cholesterol and TGs in all 
lipoprotein fractions in the medium when cultured with HS (Paper III). Conversely, the 
levels of cholesterol and TGs in the medium in SOAT2-only-Huh7.5 cells were lower 
compared with the unedited cells, independently of the culturing condition (Paper III). 
Similarly, the levels of APOB in the cell medium further increased when culturing SOAT2-
only-HepG2 cells with HS, whereas the opposite was observed in SOAT2-only-Huh7.5 cells 
(Paper III). Although SOAT1-KO had no effect on intracellular CE and TG levels in HepG2 
cells cultured with FBS, it could restore the decreased levels observed in HepG2 cells 
cultured with HS (Paper III). Conversely, SOAT1-KO in Huh7.5 cells only decreased the 
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intracellular CE levels, and the culturing with HS had the strongest effect in decreasing both 
CEs and TGs independently on the genotype (Paper III). Finally, the response to 
pharmacological cholesterol synthesis inhibition in HepG2 cells was higher when these cells 
were cultured with HS rather than with FBS.113 This was further improved in SOAT2-only-
HepG2 cells cultured with HS, which exhibited a full transcriptional response to the treatment 
with atorvastatin (Paper III). Again, the further improvements observed in SOAT2-only-
HepG2 cells cultured with HS are likely dependent of an additional increase in the expression 
of important genes involved in lipid metabolism and hepatocyte differentiation (Paper III). 
Taken together, these results underline that: (a) SOAT1 expression in hepatocyte-like cell 
lines contributes to their distorted lipid and lipoprotein phenotype, (b) the different effects 
seen with HS and SOAT1-KO (alone or in combination) strictly depend on the cellular model 
and the origin/genetic background, and (c) SOAT2-only-HepG2 cells cultured with HS 
represent a further improved in vitro model for studies of human hepatic lipid metabolism. 
4.2.2.2 Knockout of cell death-inducing DFFA-like effector c 
Genetic depletion of Soat2 in mice ameliorates dietary-induced hepatic steatosis.125, 126 
Interestingly, we noticed this to be associated with a dramatic impairment of the diet-induced 
upregulation of hepatic Fsp27 expression (unpublished data). This corroborates the 
hypothesis that the diet-induced increase in Fsp27/CIDEC plays a major role for the 
development of hepatic steatosis. After successfully using the CRISPR technology in human 
hepatocyte-like cell lines to KO SOAT1, in Paper IV we used the same methodology to 
generate a CIDEC-KO-HepG2 cellular model in order to investigate how CIDEC affects 
hepatic lipid and carbohydrate metabolism in human hepatocytes. The preliminary functional 
validation of CIDEC-KO-HepG2 cells revealed similar levels of intracellular cholesterol and 
TGs compared with the unedited HepG2 cells (Paper IV). The scarce effect on intracellular 
lipids are probably due to the low basal levels of intracellular TGs in HepG2 cells.113 
However, the analysis of gene expression indicated that CIDEC-KO may affect fatty acid 
metabolism and TG storage/secretion in HepG2 cells, although further investigations are 
needed to characterize the effects of CIDEC-KO on lipid and carbohydrate metabolism in 





5 CONCLUSION AND FUTURE PERSPECTIVE 
The primary objective of this thesis was to develop and characterize new advanced in vivo 
and in vitro preclinical models of greater relevance for human hepatic lipid and lipoprotein 
metabolism. 
As shown in Papers I and II, LHM repopulated with human hepatocytes from different 
donors exhibited a humanized lipoprotein and BA metabolism. LHM not only appeared to be 
an improved human translatable model, but also allowed to reshape the physiological 
paradigm of why humans are LDL animals and mice are non-LDL animals. We were also 
able to characterize at molecular level the pharmacodynamic effects of LXR stimulation on 
human hepatocytes, and thereby in depth understand the negative lipid outcomes of a 
previous clinical trial testing an LXR agonist. However, despite the improved liver 
metabolism, several limitations are still present in this animal model. For instance, not all 
human liver-specific factors were recapitulated, for example these mice lack expression of 
CETP and exhibit aberrant BA metabolism. While these caveats may be theoretically 
improved by humanizing the immune system as well as inserting human genes,104, 105 other 
caveats like the variable liver chimerism, the mouse peripheral metabolism and the human 
donor/mouse recipient cell interaction will always affect the complete humanization of LHM 
metabolism. Hence, in order to fully develop the potential of LHM for human 
pathophysiological studies, further improvements are required to definitively abandon the 
poorly relevant classical mouse models. 
An unequivocal hallmark of LHM is that the lipoprotein and liver metabolic phenotype is 
affected by the hepatocytes of the human donors. Several examples were indeed found 
throughout their characterization. Therefore, the combination of this aspect with the improved 
human translatability allows LHM to be used in several personalized medicine settings. 
We also explored the possibility of LHM to be used as a model of diet-induced CMD. LHM 
appeared to be resistant to HFHSD. However, LHM developed severe hepatic steatosis and 
atherosclerosis after eight-week feeding with NASH-diet despite the immune deficiency. It 
will be very important to assess whether these differences depend only on the diet 
composition or on other factors. As a matter of fact, we and our collaborators are now 
investigating whether the resistance of LHM to HFHSD is associated with glucose 
metabolism/insulin sensitivity, oxidative metabolism and in the crosstalk between the 
humanized liver and the murine host. 
In Papers III and IV we assessed whether the culturing with HS and/or the CRISPR-genome 
editing technology could improve the relevance of human hepatocyte-like cells lines for 
studies of human liver metabolism. Culturing with HS dramatically improved the lipid and 
lipoprotein phenotype of HepG2 cells. Conversely, Huh7.5 cells seem to be better suited for 
studies of lipid accumulation due to their higher basal levels of intracellular TGs. Despite the 
improved phenotype of these cells following culture with HS, both SOAT1 and SOAT2 were 
expressed in these cell lines, whereas human hepatocytes only express SOAT2 in vivo. Hence, 
none of these in vitro models cultured under standard conditions resembles the human 
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situation in vivo. The newly generated SOAT2-only-HepG2 cell line cultured with HS had a 
dramatic improved lipid phenotype. These cells may therefore be used as a new preclinical 
standard in vitro for studies of the metabolism of human hepatocytes in vivo. To extend the 
characterization of this model, the comparison between SOAT2-only-HepG2 and PHH is 
ongoing. 
We have also generated a CIDEC-KO-HepG2 cell line to study the effects of CIDEC 
inhibition on hepatic lipid and carbohydrate metabolism. The preliminary characterization of 
these cells at lipid level showed altered expression of genes involved in fatty acid metabolism 
and TG storage/secretion, but these alterations were not accompanied by significantly 
changed levels of intracellular TGs. Hence, we are planning to culture CIDEC-KO-HepG2 
cells with HS and/or under lipid-laden conditions to validate this cellular model and to assess 
the potential pathological roles of CIDEC in hepatic lipid and carbohydrate metabolism. 
Because Huh7.5 cells may be a better model for studies of hepatic steatosis/NAFLD, we have 
also knocked out CIDEC in Huh7.5 cells and we are currently screening the edited clones. As 
for CIDEC-KO-HepG2 cells, the successfully edited CIDEC-KO-Huh7.5 cells will be 
thoroughly characterized. As a final note, the versatility of the CRISPR technology allows 
several genes to be edited in the same cell line: hence, KO of CIDEC in SOAT2-only-HepG2 
and/or SOAT2-only-Huh7.5 cells may provide an even better in vitro model to investigate the 
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